Insulet (PODD) Stock Price, News & Analysis

Company Overview

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery. Insulet has advanced its platform to include systems with automated insulin delivery capabilities that integrate with continuous glucose monitoring (CGM) technologies to provide hybrid closed-loop functionality. In addition to hardware, the company offers related software, connectivity features and customer support services to enable remote monitoring and data sharing with caregivers and clinicians.

Insulet operates in multiple international markets, with sales and distribution across North America, Europe, Asia-Pacific and other regions through direct channels and local partners. The company has positioned itself around innovation in tubeless pump technology, ongoing product development and regulatory engagement to expand indications and integrations. Insulet’s business model combines recurring revenues from disposable Pods and supplies with investments in research and development, manufacturing scale-up and commercial expansion to broaden access to its insulin-delivery solutions globally.

Key Stats

• Today's Range: $141.65 to $145.13
• 50-Day Range: $142.65 to $228.63
• 52-Week Range: $140.63 to $354.88
• Volume: 2.08 million shs
• Average Volume: 1.68 million shs
• Market Capitalization: $10.04 billion
• P/E Ratio: 33.71
• Dividend Yield: N/A
• Price Target: $252.04
• Consensus Rating: Moderate Buy

Insulet Stock Analysis - MarketRank™

Insulet scored higher than 83% of companies evaluated by MarketBeat, and ranked 96th out of 871 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Insulet has received a consensus rating of Moderate Buy. The company's average rating score is 2.74, and is based on no strong buy ratings, 21 buy ratings, 5 hold ratings, and 1 sell rating.

Upside Potential

Insulet has a consensus price target of $252.04, representing about 73.9% upside from its current price of $144.94.

Amount of Analyst Coverage

Insulet has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 24.26%

Earnings Growth

Earnings for Insulet are expected to grow by 24.26% in the coming year, from $6.43 to $7.99 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Insulet is 33.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.88.

Price to Earnings Ratio vs. Sector

The P/E ratio of Insulet is 33.71, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.20.

Price to Earnings Growth Ratio

Insulet has a PEG Ratio of 1.13. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Insulet has a P/B Ratio of 7.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.37% of the float of Insulet has been sold short.

Short Interest Ratio / Days to Cover

Insulet has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Insulet has recently increased by 1.54%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Insulet does not currently pay a dividend.

Dividend Growth

Insulet does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.13

News Sentiment

Insulet has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for Insulet this week, compared to 10 articles on an average week.

Search Interest

Only 36 people have searched for PODD on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.

MarketBeat Follows

2 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Insulet insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.36% of the stock of Insulet is held by insiders.

Percentage Held by Institutions

Insulet has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 5/29/2026
• 46th Annual William Blair Growth Stock Conference: 6/03/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:PODD
• CIK: 1145197
• Web: www.insulet.com
• Phone: (978) 600-7000
• Fax: 978-600-0120
• Employees: 5,400
• Year Founded: 2000

Price Target and Rating

• Average Price Target for Insulet: $252.04
• High Price Target: $400.00
• Low Price Target: $165.00
• Potential Upside/Downside: +73.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.74
• Research Coverage: 27 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.30
• Trailing P/E Ratio: 33.71
• Forward P/E Ratio: 22.54
• P/E Growth: 1.13
• Net Income: $247.10 million
• Net Margins: 10.44%
• Pretax Margin: 13.94%
• Return on Equity: 26.87%
• Return on Assets: 12.01%

Debt

• Debt-to-Equity Ratio: 0.71
• Current Ratio: 2.49
• Quick Ratio: 1.81

Sales & Book Value

• Annual Sales: $2.71 billion
• Price / Sales: 3.71
• Cash Flow: $6.42 per share
• Price / Cash Flow: 22.56
• Book Value: $18.81 per share
• Price / Book: 7.71

Miscellaneous

• Outstanding Shares: 69,260,000
• Free Float: 69,016,000
• Market Cap: $10.04 billion
• Optionable: Optionable
• Beta: 1.20